The incidence and trends of proteinuria, azotemia and hypertension in cats receiving toceranib phosphate.

Regular monitoring of proteinuria, azotemia, and hypertension is crucial in cats treated with toceranib phosphate.

This retrospective study aimed to determine the incidence and trends of proteinuria, elevations in serum creatinine and urea, and systolic blood pressure in cats undergoing treatment with toceranib. The study included 50 cats diagnosed with various cancers, all of which received toceranib phosphate as part of their treatment regimen. The researchers monitored these cats over a period of 12 months, conducting regular assessments of urine protein-to-creatinine ratios, serum creatinine and urea concentrations, and systolic blood pressure measurements. The findings revealed that 30% of the cats developed proteinuria during the study period, with a significant increase in the protein-to-creatinine ratio observed at the 6-month mark. Elevations in serum creatinine and urea were noted in 25% and 20% of the cats, respectively, with the highest concentrations recorded at the 9-month follow-up. Hypertension was identified in 35% of the cats, with systolic blood pressure readings exceeding 160 mmHg. The study concluded that toceranib phosphate treatment in cats is associated with a notable incidence of proteinuria, azotemia, and hypertension, highlighting the importance of regular monitoring of these parameters in feline patients undergoing this therapy.

This summary was distilled by AI and may occasionally misinterpret data. Confirm critical details with the primary literature before clinical application.